Inventor · disambiguated record
John E. Knox
Also filed as: KNOX JOHN · KNOX JOHN E · KNOX JR JOHN E · KNOX JR JOHN EDWARD
22 granted patents·19 pending applications·68 citations·filing 2015–2025
94Inventor score
Files withREVOLUTION MEDICINES INC21GILEAD SCIENCES INC10IDEAYA BIOSCIENCES INC7LILAC THERAPEUTICS INC3
Top patents by PatentIndex Score
41 records- 0197US10988451B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Apr 27, 2021·10 cites·21 claims
- 0296US11739074B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Aug 29, 2023·9 cites·2 claims
- 0396US11643400B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2021·Granted May 9, 2023·4 cites·20 claims
- 0496US10703733B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2019·Granted Jul 7, 2020·12 cites·27 claims
- 0595US12202845B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jan 21, 2025·3 cites·6 claims
- 0694US12252497B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 18, 2025·3 cites·10 claims
- 0794US11690915B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2021·Granted Jul 4, 2023·9 cites·2 claims
- 0894US11168102B1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Granted Nov 9, 2021·5 cites·18 claims
- 0993US11084798B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Aug 10, 2021·3 cites·26 claims
- 1090US11130759B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Sep 28, 2021·2 cites·26 claims
- 1190US11046691B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Jun 29, 2021·2 cites·28 claims
- 1288US10040781B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2015·Granted Aug 7, 2018·3 cites·48 claims
- 1388US2025145643A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1487US2025154116A1Mcl-1 inhibitorsGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 1582US12162844B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2023·Granted Dec 10, 2024·0 cites·14 claims
- 1681US10072001B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2015·Granted Sep 11, 2018·3 cites·30 claims
- 1779US2025064787A1Heterocyclic Carboxylate Compounds as Glycolate Oxidase InhibitorsLILAC THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1879US2023106174A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Application pending·0 cites
- 1978US12168002B2Heterocyclic carboxylate compounds as glycolate oxidase inhibitorsLILAC THERAPEUTICS INC·Filed 2023·Granted Dec 17, 2024·0 cites·12 claims
- 2076US2025074923A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2176US2025361245A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2275US2025051306A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2375US2023374035A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 2473US12258366B2Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 25, 2025·0 cites·14 claims
- 2569US12503467B22-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2019·Granted Dec 23, 2025·0 cites·17 claims
- 2669US2025368661A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 2767US2025197423A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2867US2025154171A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2966US11806335B2Heterocyclic carboxylate compounds as glycolate oxidase inhibitorsLILAC THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·0 cites·12 claims
- 3065US2024262847A1Covalent ras inhibitors and uses thereofREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 3164US2021139517A1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Application pending·0 cites
- 3261US2025388598A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3361US2025129097A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3459US10253019B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2018·Granted Apr 9, 2019·0 cites·13 claims
- 3558US2023100838A1Covalent ras inhibitors and uses thereofREVOLUTION MEDICINES INC·Filed 2022·Application pending·0 cites
- 3657US12509454B2Thiadiazolyl derivativesIDEAYA BIOSCIENCES INC·Filed 2020·Granted Dec 30, 2025·0 cites·7 claims
- 3754US2024208965A1Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3854US2025269037A1Compounds, complexes, and methods for their preparation and of their useREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3952US10259811B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2018·Granted Apr 16, 2019·0 cites·10 claims
- 4044US2022305008A1Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitorsIDEAYA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4138US10316049B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2016·Granted Jun 11, 2019·0 cites·59 claims
Join the waitlist — get patent alerts
Get an alert when John E. Knox files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →